Navigation Links
AtheroNova Announces Milestone Filing of IND in Russian Federation
Date:11/13/2012

IRVINE, Calif., Nov. 13, 2012 /PRNewswire/ -- AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and to improve lipid profiles in humans, today announced that its Russian licensing partner OOO CardioNova has formally submitted its Investigational New Drug (IND) application with the Ministry of Health of the Russian Federation (Minzdrav).  This filing is the first step in the process of obtaining approval in Russia to conduct the Phase 1 human clinical trials in the centers selected by CardioNova.  It is expected that the approval of the application will be granted by the Ministry early in 2013 and the Phase 1 will commence shortly thereafter.

"We are extremely gratified in achieving this milestone in our path to human trials of AHRO-001," said AtheroNova CEO Thomas W. Gardner.  "OOO CardioNova has diligently pushed this filing forward with the utmost urgency and we want to thank them for their efforts to complete this major step in the process of clinical development of AHRO-001.  We continue to work aggressively toward our mutual goal of commencement of Phase 1 clinical trials within the next 90 days."

"We are pleased to have such a tremendous business partner in AtheroNova as we continue to endeavor toward approval of the Phase 1 protocol by the Ministry of Health," commented Dr. Alexey Eliseev, managing partner of Maxwell Biotech Group, OOO CardioNova's parent company. "Our objective is to work diligently with the Ministry of Healthcare for approval of our submission while making final preparations for the commencement of pre-screening and ultimately Phase 1 clinical trials in our Russian study centers.  We are excited with the prospect of initiating clinical trials in anticipation of potentially addressing one of the major health risks facing Russia, and throughout the world.

About AHRO-001

AHRO-001 is AtheroNov
'/>"/>

SOURCE AtheroNova Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. AtheroNova Receives Notice of Allowance for Its US Patent Application 12/024,908
2. AtheroNova Signs Agreement for Development of Clinical Trial Supplies
3. Remedy Informatics Announces Growth Capital Investment from Merck Global Health Innovation Fund
4. RPS Announces Jonathan M. Fishbein, MD as Executive Vice President and Chief Medical Officer
5. Edison Pharmaceuticals Announces Initiation of EPI-743 Phase 2B Leigh Syndrome Clinical Trial
6. Developmental Disabilities Software announces Safe Harbor Self-Certification Compliance
7. Hologic Announces Fourth Quarter and Fiscal 2012 Operating Results
8. Regulus Announces Timing for Third Quarter 2012 Financial Results Webcast and Conference Call
9. Valeritas Announces The Publication Of A Retrospective Analysis Of Patient-Reported Data On The V-Go In The Current Issue Of Endocrine Practice
10. Cynosure, Inc. Announces Proposed Public Offering of Class A Common Stock
11. 3SBio Inc. Announces Unaudited Third Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... , April 1, 2015 CSSi, ... solutions for the clinical research industry, recently partnered ... a dermatology study that was falling quickly behind ... strategies and customized site support programs, increased the ... enrolling, and also increased the number of sites ...
(Date:4/1/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/kz78wm/medical_device ) ... Device Studies: Clinical Evidence" conference to their ... specifically for those who are involved in gathering ... diagnostic products. Clinical data is required for all ... appropriate clinical evidence has grown substantially in the ...
(Date:4/1/2015)... 1, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ... new medical paper has been published describing the ... patients with severe dry eye.  The results met ... physicians stated that statistically significant differences in both ... seen at various time points throughout the study.  ...
Breaking Medicine Technology:CSSi Quadruples Screening Activity and Speeds Enrollment for Pediatric Dermatology Study 2Medical Device Studies: Clinical Evidence Seminar - London, UK, 13th, 14th of May 2015 2RegeneRx's RGN-259 Meets Key Efficacy Objectives in Phase 2 Clinical Trial in Patients with Severe Dry Eye Reported in Current Issue of Cornea 2RegeneRx's RGN-259 Meets Key Efficacy Objectives in Phase 2 Clinical Trial in Patients with Severe Dry Eye Reported in Current Issue of Cornea 3
... March 31, 2011 Delcath Systems, Inc. (NASDAQ: ... company focused on oncology, announced today the appointment of Gabriel ... immediately. The Company increased the size of its Board of ... fill this new vacancy.  Mr. Leung will serve as a ...
... Adeona Pharmaceuticals, Inc. (AMEX: AEN ), a developer of ... financial results for the year ended December 31, 2010, as well ... Updates since the beginning of the 4th quarter include: ... Adoption of " reaZin " as the ...
Cached Medicine Technology:Delcath Expands Board of Directors With Appointment of Gabriel Leung 2Delcath Expands Board of Directors With Appointment of Gabriel Leung 3Adeona Reports 2010 Year End Financial Results 2Adeona Reports 2010 Year End Financial Results 3Adeona Reports 2010 Year End Financial Results 4Adeona Reports 2010 Year End Financial Results 5Adeona Reports 2010 Year End Financial Results 6Adeona Reports 2010 Year End Financial Results 7
(Date:4/1/2015)... 01, 2015 Taking an important step ... League for Nursing Commission for Nursing Education Accreditation (NLN ... the first NLN CNEA Board of Commissioners. Working with ... the 15-member board will provide leadership and direction to ... accreditation decisions for nursing programs that seek accreditation from ...
(Date:4/1/2015)... Minn. (PRWEB) April 01, 2015 EAGAN, ... of Minnesota and its family of companies (Blue Cross) ... closed out the year with net income of $61.5 ... operational losses. The organization reported a net operating loss ... for a negative operating margin of one-tenth of one ...
(Date:4/1/2015)... San Diego, CA (PRWEB) April 01, 2015 ... promotion organization, is announcing two continuing medical education ... goal is to help practitioners become more confident ... to prevent disease. After completion of these CME ... , The CME courses available are ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 Aging2.0 ... care, today announces the launch of the Aging2.0 ... senior care stakeholders and technology companies. The announcement was ... (NIC) Capital and Business Strategies Forum in San ... the new Alliance program is now open for additional ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 When annoying ... occur, waiting days or weeks for an appointment with ... same and next day appointments haven’t been possible within ... Forefront Dermatology’s offices have noticed demand for this level ... “We realize how important relief or answers to dermatological ...
Breaking Medicine News(10 mins):Health News:NLN Commission for Nursing Education Accreditation (NLN CNEA) Announces Inaugural Commissioners 2Health News:NLN Commission for Nursing Education Accreditation (NLN CNEA) Announces Inaugural Commissioners 3Health News:Blue Cross and Blue Shield of Minnesota Reports 2014 Results 2Health News:Blue Cross and Blue Shield of Minnesota Reports 2014 Results 3Health News:GrassrootsHealth Launches CME Courses about Vitamin D 2Health News:GrassrootsHealth Launches CME Courses about Vitamin D 3Health News:Aging2.0 Announces Launch of New Membership Community, Aging2.0 Alliance 2Health News:Aging2.0 Announces Launch of New Membership Community, Aging2.0 Alliance 3Health News:Aging2.0 Announces Launch of New Membership Community, Aging2.0 Alliance 4Health News:Dermatology Associates of Wisconsin and Forefront Dermatology Answers Patients' Needs With Unmatched Availability In Sheboygan and Sheboygan Falls 2
... new study shows that a large majority of patients who present ... IV) don,t require immediate surgery to remove the primary tumor in ... data today at the American Society of Clinical Oncology Annual Meeting. ... "For this population with metastatic ...
... May 30 Wyeth Pharmaceuticals, a division of Wyeth ... The American Society of Clinical Oncology (ASCO) Cancer Foundation ... provide patients with important health information and conduct physician ... the 45th Annual Meeting of the American Society of ...
... contradicted in research paper , , FRIDAY, May 29 (HealthDay ... follow a social order do not necessarily develop bigger ... Social Brain Hypothesis followed by many evolutionists. , ... Proceedings of the National Academy of Sciences ...
... the most common reason for hospitalisation in the over-65 ... 24 hours after admission in around 50% of these ... a more than 50% mortality and rehospitalisation rate at ... Cardiology Department of the University of Brescia, Italy, "it ...
... biomarkers have been recently described in Heart Failure (HF) ... settings of acute decompensation. Biomarkers are used to diagnose ... to individuals. , Speaking at a press conference at ... spokesperson for the European Society of Cardiology, presented these ...
... the symptoms of heart failure can be remotely assessed, ... of patients, according to Professor John Cleland from the ... 2009 that the management of heart failure is complex ... needs and condition.2 "Unfortunately," he added, "the resources required ...
Cached Medicine News:Health News:Surgery not necessary for most late-stage colorectal cancers 2Health News:Wyeth Donates $100,000 to ASCO Cancer Foundation(R) to Support Cancer Prevention and Care 2Health News:Wyeth Donates $100,000 to ASCO Cancer Foundation(R) to Support Cancer Prevention and Care 3Health News:Biologists Question Animal Brain Size Theory 2Health News:Better treatment selection and improved therapies -- key to improving prognosis in acute HF 2Health News:Novel biomarkers in heart failure 2Health News:Individualized treatment for heart failure is rarely available outside hospital 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: